Skip to Content

Atossa Therapeutics Inc ATOS

Morningstar Rating
$1.80 −0.03 (1.64%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ATOS is trading within a range we consider fairly valued.
Price
$1.89
Fair Value
$2.78
Uncertainty
Extreme
1-Star Price
$38.22
5-Star Price
$5.39
Economic Moat
Tsn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATOS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.83
Day Range
$1.761.91
52-Week Range
$0.591.94
Bid/Ask
$1.80 / $1.83
Market Cap
$225.55 Mil
Volume/Avg
1.9 Mil / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.66%

Company Profile

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
11

Comparables

Valuation

Metric
ATOS
VIR
AVIR
Price/Earnings (Normalized)
Price/Book Value
2.300.860.61
Price/Sales
34.40
Price/Cash Flow
Price/Earnings
ATOS
VIR
AVIR

Financial Strength

Metric
ATOS
VIR
AVIR
Quick Ratio
27.318.6817.86
Current Ratio
28.359.0518.24
Interest Coverage
Quick Ratio
ATOS
VIR
AVIR

Profitability

Metric
ATOS
VIR
AVIR
Return on Assets (Normalized)
−18.38%−20.03%−15.46%
Return on Equity (Normalized)
−19.08%−25.63%−16.16%
Return on Invested Capital (Normalized)
−22.37%−28.31%−19.92%
Return on Assets
ATOS
VIR
AVIR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCsktslhplbFskkk$570.1 Bil
VRTX
Vertex Pharmaceuticals IncZqmpzvdclZgmwyfx$108.0 Bil
REGN
Regeneron Pharmaceuticals IncVlyqxkpzlMmdtkv$105.6 Bil
MRNA
Moderna IncVbbgtprvwNdcf$40.8 Bil
ARGX
argenx SE ADRXrrhzyqtmNzlf$23.7 Bil
BNTX
BioNTech SE ADRHzkngjdxyHsbp$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncVhsrdtbxmTnzxndd$18.8 Bil
BMRN
Biomarin Pharmaceutical IncLjjndtldGdmbs$16.5 Bil
RPRX
Royalty Pharma PLC Class AZkchdvqfqkLpnfm$13.6 Bil
INCY
Incyte CorpTxgqkqktKdtky$12.8 Bil

Sponsor Center